# Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism

> **NCT01576146** · PHASE2 · TERMINATED · sponsor: **KAI Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Secondary Hyperparathyroidism

## Interventions

- **DRUG:** Etelcalcetide

## Key facts

- **NCT ID:** NCT01576146
- **Lead sponsor:** KAI Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2014-05-01
- **Final completion:** 2014-05-01
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Study was terminated early to allow subjects to roll over to study NCT02102204.
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01576146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01576146, "Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01576146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*